Tumor-associated antigens encoded by autologous tumor stem cell mRNA

The term “tumor-associated antigens encoded by autologous tumor stem cell mRNA” refers to a personalized set of antigens derived from a patient’s own cancer stem cells, whose mRNA is isolated, amplified, and used to encode the full repertoire of tumor proteins for therapeutic vaccination. In glioblastoma and other cancers, cancer stem cells such as glioma stem cells can be cultured from patient tumor biopsies, and high-quality mRNA from these cells is transfected into autologous monocyte-derived dendritic cells to generate vaccines that present a broad spectrum of tumor-associated antigens to the immune system. These mRNA-loaded dendritic cells activate both CD4⁺ and CD8⁺ T cells against multiple neoplastic antigens, inducing polyfunctional T‑cell responses and tumor-specific immunity in preclinical and early clinical studies. This construct is not a single molecular target but rather an individualized antigen source encompassing many self and tumor-associated antigens encoded by the autologous cancer stem cell transcriptome, so it is best classified functionally as an “other” molecular class used in immunotherapy rather than as a discrete receptor or enzyme. Clinical studies in glioblastoma have shown that vaccines based on autologous cancer stem cell mRNA are feasible, safe, and associated with extended progression-free survival compared with matched controls, without notable autoimmune toxicity. However, the approach is technically demanding, expensive, and may miss antigens from tumor subclones that fail to grow under stem cell culture conditions. These mRNA-based, dendritic cell vaccines are being explored as personalized cancer immunotherapies and may be combined with immune checkpoint inhibitors or other modalities to enhance anti-tumor efficacy.

Other names

Tumor antigens encoded by autologous cancer stem cell mRNACancer stem cell antigens encoded by autologous tumor mRNAAutologous cancer stem cell–derived tumor antigensTumor-associated antigens from autologous glioma stem cell mRNACancer stem cell antigens (as a vaccine antigen source)

Induction of polyclonal T‑cell responses against multiple patient-specific tumor-associated antigens encoded by autologous cancer stem cell mRNA; Priming and expansion of CD4⁺ and CD8⁺ T cells recognizing tumor antigens presented by dendritic cells transfected with autologous tumor or cancer stem cell mRNA; Enhancement of anti-tumor immunity against glioblastoma and other cancers through broad antigen targeting via mRNA-loaded dendritic cells